Robert R Wilkening

This inventor holds 36 USPTO granted patents, plus 2 CIPO patents and 18 EPO patents, primarily in Antibacterial Compounds. Top assignees: Merck + Co., Inc., Merck Sharp + Dohme Corp., Merck Canada Inc.. Active years: 1993-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert R Wilkening. Retrieved from https://idiyas.com/inventor/robert-r-wilkening

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 36

% Patents Active = 94.4

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 18 (Patent Applications = 12)

Average Co-Inventor Count = 4.1

ph-index = 8

Forward Citations = 203(Granted Patents)

Company Filing History:

Merck Sharp + Dohme Corp.

Merck Shapr & Dohme Corp.

where one patent can have more than one assignee

Years Active: 1993-2025

Loading Chart...

Areas of Expertise:

Factor XI Inhibitors

mGluR2 Modulators

Nargenicin Compounds

Dipeptidyl Peptidase-IV

Cyclic Azabenzimidazole

Estrogen Receptor Modulators

Carbapenem Compounds

Antifungal Agents

Heterocyclic Compounds

Veterinary Antimicrobials

Amino Derivatives

Tetrahydrofuran Derivatives

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12304899 - Factor XI activation inhibitors (2025-05-20),

2. 10806724 - Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators, compositions, and their use (2020-10-20),

3. 10335399 - Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2—negative allosteric modulators, compositions, and their use (2019-07-02),

4. 10144741 - Nargenicin compounds and uses thereof as antibacterial agents (2018-12-04),

5. 10072003 - Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use (2018-09-11),

6. 9944654 - Nargenicin compounds and uses thereof as antibacterial agents (2018-04-17),

7. 9868733 - Azabenzimidazole tetrahydrofuran derivatives (2018-01-16),

8. 9556193 - Benzimidazole hexahydrofuro[3,2-b]furan derivatives (2017-01-31),

9. 9540364 - Benzimidazole tetrahydrofuran derivatives (2017-01-10),

10. 9527839 - Benzimidazole tetrahydropyran derivatives (2016-12-27),

11. 9382243 - Azabenzimidazole tetrahydropyran derivatives (2016-07-05),

12. 9290517 - Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives (2016-03-22),

13. 8980929 - Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes (2015-03-17),

14. 8853212 - Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes (2014-10-07),

15. 8796258 - Cyclic azabenzimidazole derivatives useful as anti-diabetic agents (2014-08-05),

Title: Robert R. Wilkening: Innovator in Pharmaceutical Chemistry

Introduction

Robert R. Wilkening is a distinguished inventor based in Maplewood, NJ, with an impressive portfolio of 35 patents to his name. His innovations primarily focus on pharmaceutical compounds that can be applied in treating various cognitive and mood disorders. With a commitment to advancing medical science, he has contributed significantly to the field of drug development.

Latest Patents

Wilkening's latest patents include the important work on "Chromane, isochromane, and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators, compositions, and their use." This invention features substituted chromane, isochromane, and dihydroisobenzofuran compounds that serve as mGluR2 inhibitors, or negative allosteric modulators (NAMs). These compounds hold promise for treating diseases and disorders such as Alzheimer's disease, cognitive impairment, schizophrenia, and various mood, pain, and sleep disorders. His work not only emphasizes the therapeutic applications of these compounds but also highlights their potential in pharmaceutical compositions.

Career Highlights

Throughout his career, Robert R. Wilkening has been associated with reputable companies, notably Merck & Company, Inc. and Merck Sharp & Dohme Corporation. His experience in these organizations has allowed him to refine his expertise in pharmaceutical research and development, making substantial contributions to innovative drug solutions.

Collaborations

Collaboration plays a vital role in innovation, and Wilkening has worked alongside notable professionals in the field including Ronald W. Ratcliffe and James M. Apgar. These collaborations have fostered an environment of shared knowledge, further enhancing the advancements resulting from his insights and research.

Conclusion

Robert R. Wilkening stands out as an influential inventor whose contributions to pharmaceutical chemistry are making a lasting impact on medical science. With a significant number of patents and a focus on innovative solutions for serious health conditions, Wilkening exemplifies the role of inventors in driving advancements in therapeutic options. His dedication to research and collaboration showcases the importance of innovation in the continuous fight against chronic diseases.

Profile summary based on public USPTO records.